Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT.
Pedersini
Rebecca
R
Department of Oncology, Central Hospital of Bolzano, Bolzano, Italy. rebecca.pedersini@asbz.it
Vattemi
Emanuela
E
Mazzoleni
Guido
G
Graiff
Claudio
C
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000096:biosynthesis*; D011743:Pyrimidines / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D016879:Salvage Therapy; D018239:Seminoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D013736:Testicular Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D036542:Tomography, Spiral Computed; D016896:Treatment Outcome; D015854:Up-Regulation
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit